Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
114,331,829
-
Total 13F shares
-
96,052,562
-
Share change
-
+69,852
-
Total reported value
-
$5,620,175,833
-
Put/Call ratio
-
48%
-
Price per share
-
$58.51
-
Number of holders
-
235
-
Value change
-
+$807,576
-
Number of buys
-
113
-
Number of sells
-
113
Institutional Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q4 2021
As of 31 Dec 2021,
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) was held by
235 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
96,052,562 shares.
The largest 10 holders included
Redmile Group, LLC, ARK Investment Management LLC, VANGUARD GROUP INC, BlackRock Inc., PRICE T ROWE ASSOCIATES INC /MD/, Bellevue Group AG, Casdin Capital, LLC, JOHNSON & JOHNSON, Capital World Investors, and STATE STREET CORP.
This page lists
237
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.